TTK HEALTHCARE
|
|
BOM : 507747     NSE : TTKHLTCARE     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Dec 30,2024 |
Price(EOD): ₹ 1,405.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,981.33 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
TTK HEALTHCARE | -1.7% | -3.6% | 7.2% |
SUN PHARMACEUTICAL INDUSTRIES | 3.7% | 8.5% | 49.4% |
CIPLA | 3% | 1.9% | 20.9% |
DR REDDYS LABORATORIES | 2.7% | 15.5% | 23.2% |
ZYDUS LIFESCIENCES | -1.6% | 1% | 43.9% |
DIVIS LABORATORIES | 3.6% | 1.8% | 52.1% |
MANKIND PHARMA | -4.9% | 11.4% | 49.2% |
TORRENT PHARMACEUTICALS | -1.4% | 5.3% | 49.3% |
LUPIN | 6.9% | 15.6% | 73.7% |
FUNDAMENTAL ANALYSIS OF TTK HEALTHCARE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF TTK HEALTHCARE
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
24.84
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 79.94 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 1.98
P/B Calculated based on Book Value of Rs 1,000.92 Cr
[Latest Year - Mar2024 - Standalone Results ] 2.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
50% 13% 71% |
SHARE PRICE MOMENTUM OF TTK HEALTHCARE
TTK HEALTHCARE vs SENSEX
DEBT OF TTK HEALTHCARE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.02 0.03 0.06 0.04 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF TTK HEALTHCARE
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF TTK HEALTHCARE
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-4.53% 19.13% -43.16% -45.52% |
6.85% -13.71% 7.57% 7.46% |
QtrlyTrend |
0 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
TTK HEALTHCARE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE SMALL CAP | -0.7% | 0.4% | 30.5% |
S&P BSE INDUSTRIALS | -1.9% | -2.9% | 29.3% |
S&P BSE MIDSMALLCAP | -2.3% | 1.6% | 31.3% |
You may also like the below Video Courses
FAQ about TTK HEALTHCARE
Is TTK HEALTHCARE good for long term investment?
As on Dec 30,2024, the Fundamentals of TTK HEALTHCARE look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of TTK HEALTHCARE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is TTK HEALTHCARE UnderValued or OverValued?
As on Dec 30,2024, TTK HEALTHCARE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of TTK HEALTHCARE ?
As on Dec 30,2024, the Intrinsic Value of TTK HEALTHCARE is Rs. 938.94 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 938.94
Fair Value [Median EV / Sales Model] : Rs. 1,248.11
Fair Value [Median Price / Sales Model] : Rs. 821.93
Estimated Median Fair Value of TTK HEALTHCARE : Rs. 938.94
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.